A history of medullary thyroid carcinoma Multiple endocrine neoplasia syndrome type 2 Severe gastroparesis Is insurance coverage a barrier
These risks may include: Nausea and vomiting Diarrhea or constipation Low blood sugar (especially in those with diabetes) Unknown long-term safety concerns due to a lack of research on combined use To date, the FDA has not approved the combination of semaglutide and tirzepatide for any purpose
In addition, expanding access to specialty care services and favorable treatment guidelines are strengthening demand for GLP-1 therapies throughout the country
That study used intermittent courses rather than continuous administration, establishing the template that synthetic epitalon protocols now follow
Patients who come off GLP-1s and maintain their weight are almost always the ones who built real lifestyle changes during treatment
Zeginiadou, T., Symeonidis, E